Entry of New Drugs and doctors' Prescriptions
Abstract
This paper is about entry of new drugs in pharmaceutical markets. More specifically, I analyze the diffusion of new drugs among doctors. My empirical analysis uses non-parametric duration models, which are flexible enough to identify the most important covariates influencing the doctors' adoption decisions. My results peak to issues such as why generic drugs do not have large market shares in post-patent drug markets. When I analyze entry of bio-equivalent products, I find that the doctors' past dispersion across drugs in a therapeutic market is the best predictor of the likelihood of adoption. When a new presentation form is introduced by an incumbent firm, the doctors who extensively prescribed the brand in the other presentation forms are the ones most likely to adopt the new drug. Finally, I find that doctors are not firm-loyal in their prescribing behaviour across therapeutic markets.Download Info
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.Bibliographic Info
Paper provided by Department of Economics, Royal Holloway University of London in its series Royal Holloway, University of London: Discussion Papers in Economics with number 98/13.Length: 44 pages
Date of creation: Mar 1996
Date of revision: Jan 1998
Handle: RePEc:hol:holodi:9813
Contact details of provider:
Postal: Egham Hill, Egham, Surrey, TW20 0EX, UK.
Phone: +44 1784-414228
Fax: +44 1784-439534
Web page: http://www.rhul.ac.uk/economics/
Order Information:
Postal: Egham Hill, Egham, Surrey, TW20 0EX, UK.
Email:
Related research
Keywords:Find related papers by JEL classification:
- L10 - Industrial Organization - - Market Structure, Firm Strategy, and Market Performance - - - General
- I10 - Health, Education, and Welfare - - Health - - - General
References
No references listed on IDEASYou can help add them by filling out this form.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.Cited by:
- Scott Stern & Manuel Trajtenberg, 1998.
"Empirical Implications of Physician Authority in Pharmaceutical Decisionmaking,"
NBER Working Papers
6851, National Bureau of Economic Research, Inc.
- Stern, S. & Trajtenberg, M., 1998. "Empirical Implications of Physician Authority in Pharmaceutical Decisionmaking," Papers 24-98, Tel Aviv.
Lists
This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.Statistics
Access and download statisticsCorrections
When requesting a correction, please mention this item's handle: RePEc:hol:holodi:9813For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Claire Blackman) The email address of this maintainer does not seem to be valid anymore. Please ask Claire Blackman to update the entry or send us the correct address.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.